A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells

Aoyama,Satoru; Yasuda,Shunichiro; Li,Huixin; Watanabe,Daisuke; Umezawa,Yoshihiro; Okada,Keigo; Nogami,Ayako; Miura,Osamu; Kawamata,Norihiko

doi:10.3892/ijmm.2022.5097

A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells

Authors:
- Satoru Aoyama
- Shunichiro Yasuda
- Huixin Li
- Daisuke Watanabe
- Yoshihiro Umezawa
- Keigo Okada
- Ayako Nogami
- Osamu Miura
- Norihiko Kawamata
View Affiliations

Affiliations: Department of Immunotherapy for Hematopoietic Disorders, Tokyo Medical and Dental University (TMDU), Tokyo 113‑8510, Japan, Department of Hematology, Tokyo Medical and Dental University (TMDU), Tokyo 113‑8510, Japan, Department of Hematology
Published online on: February 4, 2022 https://doi.org/10.3892/ijmm.2022.5097
Article Number: 42
Copyright: © Aoyama et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anti‑CD19 chimeric antigen receptor (CAR)‑T cell therapy against refractory B‑cell malignancies shows excellent therapeutic effects. However, there are some obstacles to be overcome in this treatment. Since current CAR‑T cells target a single cell‑surface protein on tumor cells, the CAR‑T cells also attack normal cells expressing the protein. This is one of the major adverse effects of this therapy. To improve target‑cell‑specificity of this therapy, we established a novel CAR system, in which T‑cell activation was controlled by expression patterns of proteins on target cells. Our novel CAR‑T cells had two distinct CARs consisting of a ‘Signal‑CAR’, recognizing a protein on tumor cells, and a ‘Scissors‑CAR’, recognizing another protein on normal cells. The signal‑CAR had a peptide sequence which was cleaved by the Scissors‑CAR, and functional domains for cellular activation. The Scissors‑CAR had a protease domain that cleaved its recognition peptide sequence in the Signal‑CAR. When tumor cells expressed only the protein recognized by the Signal‑CAR, the tumor cells were attacked. By contrast, normal cells expressing both the proteins induced inactivation of the Signal‑CAR through cleavage of the recognition site when getting in contact with the CAR‑T cells. To establish this system, we invented a Scissors‑CAR that was dominantly localized on cell membranes and was activated only when the CAR‑T cells were in contact with the normal cells. Using a T‑cell line, Jurkat, and two proteins, CD19 and HER2, as target proteins, we showed that the anti‑CD19‑Signal‑CAR was cleaved by the anti‑HER2‑Scissors‑CAR when the CAR‑T cells were co‑cultivated with cells expressing both the proteins, CD19 and HER2. Furthermore, we demonstrated that primary CAR‑T cells expressing both the CARs showed attenuated cytotoxicity againsT cells with both the target proteins. Our novel system would improve safety of the CAR‑T cell therapy, leading to expansion of treatable diseases by this immunotherapy.

View Figures

View References

1	Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al: Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018. View Article : Google Scholar : PubMed/NCBI
2	Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar
3	Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, Rosenberg SA and Kochenderfer JN: Long-term follow-up of Anti-CD19 chimeric antigen receptor T-Cell therapy. J Clin Oncol. 38:3805–3815. 2020. View Article : Google Scholar : PubMed/NCBI
4	Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33:540–549. 2015. View Article : Google Scholar :
5	Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, et al: Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019. View Article : Google Scholar
6	Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI
7	Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 119:2709–2720. 2012. View Article : Google Scholar
8	Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 21:581–590. 2015. View Article : Google Scholar : PubMed/NCBI
9	Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, Anbunathan H, Lattin J, Jones R, Tieu V, et al: c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 576:293–300. 2019. View Article : Google Scholar
10	Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA and Lim WA: Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 167:419–432.e416. 2016. View Article : Google Scholar : PubMed/NCBI
11	Taube R, Zhu Q, Xu C, Diaz-Griffero F, Sui J, Kamau E, Dwyer M, Aird D and Marasco WA: Lentivirus display: Stable expression of human antibodies on the surface of human cells and virus particles. PLoS One. 3:e31812008. View Article : Google Scholar : PubMed/NCBI
12	Lindsten K, Uhlíková T, Konvalinka J, Masucci MG and Dantuma NP: Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity. Antimicrob Agents Chemother. 45:2616–2622. 2001. View Article : Google Scholar : PubMed/NCBI
13	Weissman AM, Hou D, Orloff DG, Modi WS, Seuanez H, O'Brien SJ and Klausner RD: Molecular cloning and chromosomal localization of the human T-cell receptor zeta chain: Distinction from the molecular CD3 complex. Proc Natl Acad Sci USA. 85:9709–9713. 1988. View Article : Google Scholar
14	Conchello JA and Lichtman JW: Optical sectioning microscopy. Nat Methods. 2:920–931. 2005. View Article : Google Scholar : PubMed/NCBI
15	Kanda Y: Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar
16	Navia MA and McKeever BM: A role for the aspartyl protease from the human immunodeficiency virus type 1 (HIV-1) in the orchestration of virus assembly. Ann NY Acad Sci. 616:73–85. 1990. View Article : Google Scholar : PubMed/NCBI
17	Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD and Hochstrasser DF: Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 112:531–552. 1999.PubMed/NCBI
18	Liu Z, Chen O, Wall JB, Zheng M, Zhou Y, Wang L, Vaseghi HR, Qian L and Liu J: Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Sci Rep. 7:21932017. View Article : Google Scholar : PubMed/NCBI
19	Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289. 1992. View Article : Google Scholar : PubMed/NCBI
20	Cho JH, Collins JJ and Wong WW: Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 173:1426–1438.e1411. 2018. View Article : Google Scholar :
21	Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al: SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 13:eabe73782021. View Article : Google Scholar :
22	Fedorov VD, Themeli M and Sadelain M: PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 5:215ra1722013. View Article : Google Scholar
23	Mager PP: The active site of HIV-1 protease. Med Res Rev. 21:348–353. 2001. View Article : Google Scholar : PubMed/NCBI
24	Boice M, Salloum D, Mourcin F, Sanghvi V, Amin R, Oricchio E, Jiang M, Mottok A, Denis-Lagache N, Ciriello G, et al: Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells. Cell. 167:405–418.e413. 2016. View Article : Google Scholar : PubMed/NCBI
25	Lamers CH, Klaver Y, Gratama JW, Sleijfer S and Debets R: Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview. Biochem Soc Trans. 44:951–959. 2016. View Article : Google Scholar
26	Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851. 2010. View Article : Google Scholar : PubMed/NCBI